Biotron Limited (AU:BIT) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Biotron Limited reported mixed results from its Phase 2 COVID-19 trial for the antiviral drug BIT225, which met safety and tolerability endpoints but not efficacy targets. Despite this, Biotron continues to advance its research on antiviral compounds, including promising developments in HIV-1 and Dengue virus programs. The company remains committed to exploring commercial opportunities for its unique viroporin antagonist platform, which shows broad-spectrum antiviral activity.
For further insights into AU:BIT stock, check out TipRanks’ Stock Analysis page.
